```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson's disease, although its true function, including its physiological substrates, remains unknown. Data suggest that the kinase activity of LRRK2 may play a key role in neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The paper defines LRRK2's involvement in autosomal-dominant familial Parkinson's disease and suggests its kinase activity is linked to neurodegeneration.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "in vitro kinase assay with recombinant proteins, we demonstrated for the first time that LRRK2 directly phosphorylates Akt1. The disease-associated mutations, R1441C, G2019S, and I2020T, exhibited reduced interaction with, and phosphorylation of, Akt1, suggesting one possible mechanism for the neurodegeneration caused by LRRK2 mutations.",
          "judgment": "Yes",
          "reasoning": "The kinase activity assay directly assesses LRRK2's function in phosphorylating Akt1, which is relevant to the disease mechanism of neurodegeneration.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Fig. 5A Recombinant His-Akt1 (native) was incubated with recombinant GST-LRRK2 of the wild-type (WT), G2019S mutant, I2020T mutant, or R1441C mutant in the presence of cold y-ATP...Fig. 5B Graphical representation of the Akt1 (S473) phosphorylation level. Stars represent statistical comparisons by one-way ANOVA (n = 3)",
          "judgment": "Yes",
          "reasoning": "The experiment used wild-type LRRK2 as a normal control and performed the experiment in triplicate (n=3).",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "no known pathogenic or benign variants were used as controls.",
          "judgment": "No",
          "reasoning": "The study did not use known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": null,
          "judgment": null,
          "reasoning": "Proceeding to step 4 since variant controls were not used.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "no benign/pathogenic variant controls were used",
          "judgment": "No",
          "reasoning": "Since no known benign/pathogenic variants were used, the total is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R1441C variant shows decreased phosphorylation activity compared to wild-type LRRK2, and the experimental design, including controls and replicates, supports a pathogenic effect, giving it a PS3_supporting strength."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson's disease, although its true function, including its physiological substrates, remains unknown. Data suggest that the kinase activity of LRRK2 may play a key role in neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The paper defines LRRK2's involvement in autosomal-dominant familial Parkinson's disease and suggests its kinase activity is linked to neurodegeneration.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "in vitro kinase assay with recombinant proteins, we demonstrated for the first time that LRRK2 directly phosphorylates Akt1. The disease-associated mutations, R1441C, G2019S, and I2020T, exhibited reduced interaction with, and phosphorylation of, Akt1, suggesting one possible mechanism for the neurodegeneration caused by LRRK2 mutations.",
          "judgment": "Yes",
          "reasoning": "The kinase activity assay directly assesses LRRK2's function in phosphorylating Akt1, which is relevant to the disease mechanism of neurodegeneration.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Fig. 5A Recombinant His-Akt1 (native) was incubated with recombinant GST-LRRK2 of the wild-type (WT), G2019S mutant, I2020T mutant, or R1441C mutant in the presence of cold y-ATP...Fig. 5B Graphical representation of the Akt1 (S473) phosphorylation level. Stars represent statistical comparisons by one-way ANOVA (n = 3)",
          "judgment": "Yes",
          "reasoning": "The experiment used wild-type LRRK2 as a normal control and performed the experiment in triplicate (n=3).",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "no known pathogenic or benign variants were used as controls.",
          "judgment": "No",
          "reasoning": "The study did not use known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": null,
          "judgment": null,
          "reasoning": "Proceeding to step 4 since variant controls were not used.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "no benign/pathogenic variant controls were used",
          "judgment": "No",
          "reasoning": "Since no known benign/pathogenic variants were used, the total is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The G2019S variant shows decreased phosphorylation activity compared to wild-type LRRK2, and the experimental design, including controls and replicates, supports a pathogenic effect, giving it a PS3_supporting strength."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is the causal molecule for autosomal-dominant familial Parkinson's disease, although its true function, including its physiological substrates, remains unknown. Data suggest that the kinase activity of LRRK2 may play a key role in neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The paper defines LRRK2's involvement in autosomal-dominant familial Parkinson's disease and suggests its kinase activity is linked to neurodegeneration.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "in vitro kinase assay with recombinant proteins, we demonstrated for the first time that LRRK2 directly phosphorylates Akt1. The disease-associated mutations, R1441C, G2019S, and I2020T, exhibited reduced interaction with, and phosphorylation of, Akt1, suggesting one possible mechanism for the neurodegeneration caused by LRRK2 mutations.",
          "judgment": "Yes",
          "reasoning": "The kinase activity assay directly assesses LRRK2's function in phosphorylating Akt1, which is relevant to the disease mechanism of neurodegeneration.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Fig. 5A Recombinant His-Akt1 (native) was incubated with recombinant GST-LRRK2 of the wild-type (WT), G2019S mutant, I2020T mutant, or R1441C mutant in the presence of cold y-ATP...Fig. 5B Graphical representation of the Akt1 (S473) phosphorylation level. Stars represent statistical comparisons by one-way ANOVA (n = 3)",
          "judgment": "Yes",
          "reasoning": "The experiment used wild-type LRRK2 as a normal control and performed the experiment in triplicate (n=3).",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "no known pathogenic or benign variants were used as controls.",
          "judgment": "No",
          "reasoning": "The study did not use known pathogenic or benign variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": null,
          "judgment": null,
          "reasoning": "Proceeding to step 4 since variant controls were not used.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "no benign/pathogenic variant controls were used",
          "judgment": "No",
          "reasoning": "Since no known benign/pathogenic variants were used, the total is less than 10.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The I2020T variant shows decreased phosphorylation activity compared to wild-type LRRK2, and the experimental design, including controls and replicates, supports a pathogenic effect, giving it a PS3_supporting strength."
    }
  ]
}
```